CC
VRTX icon

Centiva Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Centiva Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,200
Closed -$22.8M – 2053
2025
Q4 		$22.8M Sell
50,200
-50,000
-50% -$21.6M 0.19% 93
2025
Q3 		$39.2M Buy
+100,200
New +$41.9M 0.37% 47
2025
Q1 		– Sell
-600
Closed -$242K – 2184
2024
Q4 		$242K Sell
600
-400
-40% -$185K 0.01% 1267
2024
Q3 		$465K Hold
1,000
– – 0.01% 1295
2024
Q2 		$469K Sell
1,000
-100
-9% -$43.4K 0.01% 1194
2024
Q1 		$460K Sell
1,100
-8,000
-88% -$3.38M 0.01% 1032
2023
Q4 		$3.7M Buy
9,100
+100
+1% +$36.9K 0.09% 218
2023
Q3 		$3.13M Buy
9,000
+2,500
+38% +$874K 0.07% 259
2023
Q2 		$2.29M Hold
6,500
– – 0.05% 339
2023
Q1 		$2.05M Sell
6,500
-14,000
-68% -$4.2M 0.05% 398
2022
Q4 		$5.92M Sell
20,500
-5,000
-20% -$1.52M 0.17% 126
2022
Q3 		$7.38M Buy
25,500
+12,000
+89% +$3.45M 0.14% 97
2022
Q2 		$3.8M Sell
13,500
-600
-4% -$161K 0.09% 195
2022
Q1 		$3.68M Buy
14,100
+9,100
+182% +$2.16M 0.07% 244
2021
Q4 		$1.1M Buy
+5,000
New +$972K 0.02% 580
2021
Q3 		– Sell
-5,000
Closed -$1.01M – 1634
2021
Q2 		$1.01M Buy
+5,000
New +$1.05M 0.02% 567
2020
Q4 		– Sell
-4,100
Closed -$1.11M – 1122
2020
Q3 		$1.11M Hold
4,100
– – 0.07% 186
2020
Q2 		$1.19M Sell
4,100
-3,400
-45% -$922K 0.07% 151
2020
Q1 		$1.78M Buy
+7,500
New +$1.72M 0.08% 153
2019
Q2 		– Sell
-1,500
Closed -$276K – 512
2019
Q1 		$276K Buy
+1,500
New +$277K 0.02% 263

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Centiva Capital's VRTX Position: Q1 2026 in Review

Centiva Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 2,147 shares worth $959K. The stake represents 0.01% of the portfolio and ranks #610 among its holdings. This is a return to the name: Centiva Capital previously reported a position in VRTX as recently as Q1 2025.

Centiva Capital first reported a position in VRTX in Q1 2019 and has held it in 22 quarters since. The position peaked at $3.68M in Q2 2023. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Centiva Capital held 2,147 shares of Vertex Pharmaceuticals worth $959K as of Q1 2026.
  • Vertex Pharmaceuticals was a new Centiva Capital position in Q1 2026.
  • Vertex Pharmaceuticals made up 0.01% of Centiva Capital's portfolio in Q1 2026, its #610 holding.
  • Centiva Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 22 quarters since.
  • Centiva Capital's Vertex Pharmaceuticals position peaked at $3.68M in Q2 2023.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.